Recurrent Masses after Testicular Cancer: Growing Teratoma Syndrome. A Case Report and Review of the Literature

Autor: Fanny Priod, Francis Lorge, Marcelo Di Gregorio, Michaël V. Dupont, Marie-Cécile Nollevaux, Laurence Faugeras, Georges Lawson, Philippe Eucher, Lionel D’Hondt

Publikováno v: Case Reports in Oncology, Vol 10, Iss 3, Pp 910-915 (2017)

Background: Growing teratoma syndrome is a rare syndrome that affects patients with nonseminomatous germ-cell tumors (NSGCTs). It is characterized by recurrent growing masses that appear during or after chemotherapy in the presence of normal levels o

Externí odkaz: https://doaj.org/article/43857b2b8d544dc39330d3800a93d92b

Refractory thyroid carcinoma: which systemic treatment to use?

Autor: Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Luc Michel, Julien Lemaire, Sebastien Vandervorst, Lionel D’Hondt

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 10 (2018)

The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on

Externí odkaz: https://doaj.org/article/ac357fd5e615437fa0b62408e8a3d877

Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital

Autor: Thierry De Ronde, Laurence Faugeras, Claude Bertrand, Abdenor Badaoui, Alexandra Dili, Axel Baily, Jean-Paul Martinet, Quentin Gilliaux, Monique Delos, Jacques Jamart, Lionel D'Hondt

Publikováno v: Journal of gastrointestinal cancer, Vol. 52, no. 3, p. 1003-1009 (2020)

Biliary tract and gallbladder cancers are rare tumors with a poor prognosis (except the ampulla type). The evolution of hepatobiliary cancer incidence varies widely around the world. According to the Belgian Cancer Registry, the number of hepatobilia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf0d61ddcd5d64110a04990e3548ebd
https://pubmed.ncbi.nlm.nih.gov/32984916

Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Autor: Valentina Boni, Jessica Bauman, Antonio Gualberto, Myung-Ju Ahn, Laurence Faugeras, Sung-Bae Kim, Caroline Even, Keith C. Bible, Ioanna Nixon, Kevin J. Harrington, Catherine Rose Scholz, Binaifer Balsara, Nabil F. Saba, Maria Jose Flor, Lisa Licitra, Alan L. Ho, Irene Brana, Pol Specenier, Robert I. Haddad, Jeanne Britt, V. Mishra, Deborah J. Wong, Cyrus Sayehli, Sjoukje F. Oosting, Jérôme Fayette, Francis P. Worden

Publikováno v: Molecular Cancer Therapeutics. 18:PR08-PR08

Background: This Phase 2 study (NCT02383927) is a multi-institutional, open-label trial to determine the efficacy and safety of tipifarnib in patients (pts) with locally advanced/unresectable and/or metastatic solid tumors that carry HRAS missense mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18d5f2482ddac253f78714c09a0d186a
https://doi.org/10.1158/1535-7163.targ-19-pr08

Refractory thyroid carcinoma: which systemic treatment to use?

Autor: Lionel D'Hondt, Luc Michel, Julien Lemaire, Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Sebastien Vandervorst

Publikováno v: Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Therapeutic Advances in Medical Oncology, Vol. 10, p. 1-14 (2018)

The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce45aae136e1867565d6776d9973488
https://pubmed.ncbi.nlm.nih.gov/29399055